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Worldwide, the impact of meningococcal disease is substantial, and the potential for the introduction and spread of
more virulent strains of N. meningitidis or strains with increased resistance to current antibiotics causes concern, making
prevention essential.
OBJECTIVES: Review the indications for meningococcal disease vaccines, considering the epidemiological status
in Brazil.
METHODS: A critical literature review on this issue using the Medline and Lilacs databases.
RESULTS: In Brazil, MenB and MenC were the most important serogroups identified in the 1990s. Polysaccharide
vaccines available against those serogroups can offer only limited protection for infants, the group at highest risk for
meningococcal disease. Additionally, polysaccharide vaccines may induce a hypo-responsive state to MenC. New
meningococcal C conjugate vaccines could partially solve these problems, but it is unlikely that in the next few years a
vaccine against MenB that can promote good protection against multiple strains of MenB responsible for endemic and
epidemic diseases will become available.
CONCLUSIONS: In order to make the best decision about recommendations on immunization practices, better quality
surveillance data are required. In Brazil, MenC was responsible for about 2,000 cases per year during the last 10 years. New
conjugate vaccines against MenC are very effective and immunogenic, and they should be recommended, especially for
children less than 5 years old. Polysaccharide vaccines should be indicated only in epidemic situations and for high-risk
groups. Until new vaccines against MenC and MenB are available for routine immunization programs, the most important
measure for controlling meningococcal disease is early diagnosis of these infections in order to treat patients and to offer
chemoprophylaxis to contacts.
DESCRIPTORS: Neisseria meningitidis. Epidemiology. Vaccine. Efficacy. Children.
Meningococcal diseases (MD) are
endemic everywhere in the world, but
they have a great potential to cause
epidemics. Due to the high mortality
rates and serious sequelae when epi-
demics develop, even a small number
of cases cause great concern. Although
there are commercially available
polysaccharide vaccines to prevent
MD caused by the main meningococ-
cus serogroups, such vaccines are un-
able to produce long-lasting immunity
and are poorly effective in preventing
MD in infants, the largest group at risk
for these infections1-11.
In February 2002, a new conjugate
vaccine against serogroup C meningo-
coccus (MenC) was licensed in Brazil.
This vaccine has been included in the
vaccination schedule in the United
Kingdom since 199910,11 . Since this
vaccine is little known by pedia-
tricians, we present in this paper a lit-
erature review on the association of
MenC immunity and prevention of the
MD caused by this agent, taking into
consideration the epidemiological sta-
tus in Brazil.
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Immunity against N. meningitidis
Newborns acquire IgG class anti-
bodies from their mothers through the
placenta; these antibodies are effective
against a few meningococcus
serogroups. As these antibodies be-
come catabolized, the child becomes
susceptible to infections, which occur
in general after the third month of life.
Non-vaccinated children exhibit a
progressive growth of the geometric
mean titer (GMT) of antibodies against
meningococci in response to the colo-
nization of the airways by different
kinds of Neisseria (typed or not, in-
cluding related strains such as N.
lactamica). A few strains of E. coli and
other bacteria that normally colonize
the intestine have a polysaccharide
capsule or other antigens in the cap-
sule wall that are immunologically
identical or very similar to the N.
meningitidis antigens, thus contribut-
ing to natural immunization1,4,7,12,13.
Asymptomatic carriers of N.
meningitidis begin to produce anti-
bodies, on the average, 2 weeks after
nasopharyngeal colonization has
started. Acquisition of natural immu-
nity against serogroup A meningococ-
cus (MenA) occurs earlier than immu-
nity to other serogroups. In the United
States, more than 90% of children aged
18 months have MenA antibodies; the
same protection level against MenC is
only reached after 6 to 8 years. It is be-
lieved that the majority of these anti-
bodies are acquired due to cross-reac-
tivity between N. meningitidis anti-
gens and those of enterobacteriae4,7,12,13.
Tolerance to serogroup B meningococ-
cus (MenB) polysaccharides antigens
occurs due to the similarity between
MenB capsular antigens and nervous
tissue antigens; the majority of the an-
tibacterial antibodies against MenB
target sub-capsular antigens14-16.
Since the 1960’s, it has been dem-
onstrated that there is a direct associa-
tion between the absence of serum an-
tibacterial antibodies and MD suscep-
tibility; however, so far, the titer of an-
tibodies required to protect against the
disease is unknown. During epidemics,
it has been observed that the majority
of children and adults who had anti-
body titers higher than 2 mg/L (10
times more than those found in patients
with agammaglobulinemia) were pro-
tected against serogroups A and C in-
fections. There are no studies available
on protection titers against serogroups
Y and W1351,3,7,8 .
Complement, especially the C5
and C9 fractions, is also important in
protecting against MD, and the spleen
plays an essential role in removing in-
completely opsonized bacteria from
the blood stream. People with comple-
ment deficiency or asplenia exhibit a
greater risk for MD, and frequently
these infections are caused by uncom-
mon serogroups1,3,5,7,8.
Polysaccharide vaccines against
Neisseria meningitidis
Currently available polysaccharide
vaccines (monovalent A and C, biva-
lent A/C, and quadrivalent A, C, Y and
W135) are safe and effective in reduc-
ing the number of cases during epi-
demics1-9,17. However, their
immunogenicity is low, especially for
younger children1-9,12-28.
During epidemics, polysaccharide
vaccines against MenA and MenC, ad-
ministered to school age children, ado-
lescents, and adults, demonstrated
above 85% efficacy; however, in chil-
dren under 2, the vaccine against
MenC has a low efficiency1-9,17-28.
In a controlled study performed in
Brazil involving 135,000 children aged
between 6 and 36 months, Taunay et
al.18 found that the vaccine was effec-
tive in only 55% of the individuals be-
tween 24 and 36 months of age, and no
efficacy was observed in those below 2
years of age, after 17 months of follow-
up. Probably, the low efficacy of the
vaccine against MenC is due to its re-
duced capacity to stimulate formation
of antibacterial antibodies in children
less than 2 years of age19.
The low immunogenicity of MenA
and MenC polysaccharide vaccines in
younger children1-11,20-28 is due to the
inability of the polysaccharide anti-
gens to stimulate a T-dependent immu-
nologic response24-28. Repeated doses
of polysaccharide antigens are not only
unable to cause a booster response, but
they may actually cause immunologic
tolerance29-33 . Studies conducted with
children29-32 and adults33 previously
vaccinated against MenC who were
vaccinated again 1 to 4 years after re-
ceiving the first vaccine dose showed
low antibacterial antibody titers
against MenC (< 1:8), in contrast with
those individuals who had never been
vaccinated or who had received a new
conjugated vaccine against MenC.
It is difficult to assess the clinical
importance of these findings. Theoreti-
cally, it is possible that individuals
who received the MenC polysaccha-
ride vaccine become more prone to de-
veloping invasive disease caused by
these bacteria due to reduced antibody
levels after exposure to MenC1,29-33 .
Polysaccharide vaccines against
MenB have low immunogenicity in hu-
mans despite the fact that MenB and
MenC polysaccharides are very similar14-
16
. Low immunogenicity of MenB cap-
sule polysaccharides has been one of the
main barriers in the development of
vaccines against this serogroup of N.
meningitidis. There are, however, a few
indications that antibacterial antibodies
against MenB subcapsular antigens may
produce some degree of immunity
against these bacteria; therefore, the de-
velopment of new vaccines against
MenB is based on these antigens1,7,15-16.
Conjugated vaccines against MenA
and MenC
After the conjugated vaccines were
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developed and had proven to be highly
effective against Haemophilus
influenzae type b (Hib) in infants, there
have been many attempts to develop
new vaccines against N. meningitidis
by conjugating the bacteria capsule
polysaccharides with the same carrier
proteins used in the development of
conjugated vaccines against Hib. Al-
though MenA, MenC, MenY, and
MenW-135 polysaccharides have been
conjugated with different kinds of pro-
teins, published data on safety and
immunogenicity of these vaccines in
humans only deal with MenA ad
MenC31-41 .
A number of studies have already
demonstrated that the new conjugated
vaccines against MenA and MenC are
highly immunogenic in children, ado-
lescents, and adults9,29-40. Twumasi et
al.34 assessed the immunologic re-
sponse in 304 children (aged between
8 and 10 weeks) after 3 doses of a con-
jugated vaccine A/C, compared with
the polysaccharide vaccine. The con-
jugated vaccine was found to be as
safe as the polysaccharide vaccine.
Moreover, antibody titers after 2 doses
of the conjugated vaccine were higher
than those obtained after the use of the
polysaccharide vaccine. In children
over 6 months of age, a conjugated
vaccine dose induced higher antibody
titers against MenC than 2 doses of the
same vaccine administered at 2 and 6
months.
Similar results have been observed
by different investigators in studies
performed in the United States36,
United Kingdom9,35,39,41, and Af-
rica29,31,34. In all these studies, MenC
bactericidal antibody production after
administration of conjugated vaccines
was much higher than that obtained
after the use of the polysaccharide
vaccine. One month after the menin-
gococcal conjugated vaccination,
91% to 100% of children had serum
bactericidal antibody (SBA) ≥ 8, and
89% to 100% had a ≥ 4-fold increase.
Serum bactericidal geometric mean
titers (GMTs) of anti-MenC antibodies
increased more than 50 times after ad-
ministration of 3 different meningococ-
cal C conjugated vaccines. By 6
months, GMTs decreased, but IgG an-
tibody avidity increased. After a
polysaccharide vaccine booster, there
is a further increase in avidity and
higher GMT, suggesting that conju-
gated vaccines can induce immuno-
logic memory1,42.
Conjugated MenC vaccines con-
tain no live component and cannot
give anyone meningitis or septicemia.
The main adverse events include local
transient reactions that normally re-
solve within 1 or 2 days. Less than 5%
of vaccinated infants and toddlers de-
velop local erythema or swelling ≥ 3
cm within 7 days at the meningococ-
cal conjugated vaccine injection site,
and 2% have low fever. Children
above 5 years and adolescents pre-
sented the highest rate of local reac-
tions that include redness and/or
edema (25%) and pain in the injection
site (1%), and the same rate of in-
creased temperature. All such reactions
remitted within 1 or 2 days and were
not significantly higher than those ob-
served after administration of vaccines
against hepatitis B, Hib, and inacti-
vated poliovirus vaccine1,31-42.
Presentations and dosage admin-
istration – Three MenC conjugated
vaccines licensed in Europe and 2 in
Brazil are currently commercially
available. Two of the 3 meningococ-
cal conjugated vaccines contain short-
chain oligosaccharides (10 µg)
derived from serogroup C capsular
polysaccharide (O-acetylated), coupled
to CRM197 , a nontoxic mutant of diph-
theria toxin (Chiron Vaccines and
Wyeth Lederle Vaccines and
Pediatrics). The third contains
serogroup C polysaccharide (10 µg of
O-acetylated), conjugated to tetanus
toxoid (MCC-TT; North American Vac-
cine – NAVA)42.
The United Kingdom was the first
country to license and recommend rou-
tine immunization with MenC conju-
gated vaccines in 1999. Single dose
vaccine is recommended for children
older than 1 year; when the immuni-
zation program is initiated in children
aged 5 to 12 months, 2 doses were rec-
ommended, and between 2 and 5
months, 3 doses, with a 1-month inter-
val (Table 1)10,11,42 .
Table 1 - Immunization schedule for conjugated vaccines against N. meningitidis C used in the United Kingdom.
Age group Conjugated vaccine Comments
< 5 months 3 doses, with a minimum 4 week interval In the United Kingdom, conjugated vaccines are
recommended for 2-, 3-, and 4-month-old children
together with the vaccines DPT-Hib and poliovirus oral
vaccine.
5 to 12 months 2 doses, with one month interval
Children over 1 year, 1 dose only
adolescents and adults *
*After the age of 2, immunocompromised individuals should receive a quadrivalent polysaccharide vaccine dose.
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In Brazil, the first conjugated
MenC vaccine was licensed in Febru-
ary 2002 (Meningitec, Wyeth Labora-
tories). The serogroup C polysaccha-
ride conjugated to tetanus toxoid
(NeisVac-C, Baxter) was also licensed
in 2002. The manufacturer’s recom-
mendations should be followed with
regard to the number of doses and ad-
ministration intervals.
Efficacy of conjugated vaccines in
the United Kingdom (UK) – Conju-
gated MenC vaccines have had a high
efficacy against MD41,42. From Novem-
ber 1999 until November 2000, about
14 million people younger than 18
years had been immunized with con-
jugated MenC vaccines in the UK.
Age-specific vaccine efficacy had
been estimated to be 88% in children
aged 12 to 30 months and 96% in ado-
lescents aged 15 to17 years. Addition-
ally, conjugated MenC vaccines re-
duced carriage of serogroup C menin-
gococci in 15 to 17 year-old school
students in the UK by 66% and pro-
duced no significant changes in car-
riage of meningococci expressing
other disease-associated serogroups42.
These vaccines were highly
immunogenic and induced immuno-
logic memory after a single dose in UK
toddlers. There was no serious adverse
event associated with their use in chil-
dren and adolescents41-43.
Comments on the use of conjugated
MenC vaccines, considering the epi-
demiology of MD in Brazil.
In Brazil, local meningococcal
meningitis outbreaks caused by
serogroups B and C have occurred
since the 1980s.44-46 The Health Min-
istry and the State of São Paulo Health
Secretary data indicate that in this
country prevalence and mortality rates
of MD are extremely high, especially
in children younger than 5 years (Ta-
bles 2 and 3)45,46. Although serogroup
B is the most prevalent in children
with MD, a progressive increase in the
number of serogroup C cases has been
recorded. While in the 1980s, over
80% of meningitis cases due to N.
meningitidis were ascribed to MenB,
in the 1990s, this rate came down to
50% to 60%, while MenC reached a
40% to 50% level (Table 4)1,45,46.
In different countries, there has
been an increase not only in the inci-
dence rate of MD caused by MenC,
but also an increase in the mortality
Table 2 - Meningococcal disease in Brazil. Distribution of confirmed cases, prevalence coefficient, mortality numbers, and
rates, in the year 2000.
Age group Cases Coefficients /100,000 Deaths Mortality rate
(years) (number) (number) (%)
< 1 817 24.5 197 24
1 – 4 1,379 10.3 273 20
5 – 9 825 4.7 120 15
10-14 497 2.7 67 13
15-19 305 1.7 36 12
20 – 29 311 1.1 60 19
30 – 39 193 0.8 44 23
40 –49 121 0.7 23 19
50 – 59 83 0.7 22 27
60 – 69 30 0.4 8 27
70 –79 21 0.5 11 52
> 80 1 0.07 0 0
Total 4,583 6.1 862 22
Source: Health Ministry, “Fundação Nacional de Saúde” (unpublished and not final data, March 2002).
Table 3 - Number of cases, mortality numbers, and rate of Meningococcal diseases according to age group. State of São
Paulo, year 2000.
Age group Cases Deaths Mortality rate
(years) (number) (number) (%)
< 1 343 76 22
1 – 4 592 118 20
5 – 9 263 34 13
10-14 105 16 15
15-19 88 9 10
20 – 39 166 32 19
³ 40 86 21 24
Total 1,643 306 19
Source: São Paulo, “Centro de Vigilância Epidemiológica”46.
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rate associated with this serogroup4,6-
9-11
. This problem has been attributed
to the emergence and spread of highly
aggressive MenC strains belonging to
the ET-37 complex1,47-49. Unfortu-
nately, in Brazil, the etiological agent
is identified in less than 50% of the
cases and serogrouping is performed in
approximately one-third of the
cases1,45,46.
Since it is not always possible to
isolate the bacterial meningitis agents,
and very often, the isolates are not
typed, the prevalence of MD is under-
estimated. Even so, during the last 10
years, the number of MD cases has
been extremely high. In the 1990’s, an
average of 5,680 MD cases and 1,085
deaths (19%) have been reported each
year. Distribution of the number of MD
cases and deaths, and mortality rate
due to MD in Brazil in 2000, sepa-
rated by age-groups, is reported in ta-
ble 21. Almost half the cases and
deaths (45%) occurred in children un-
der 5 years45. In the state of São Paulo,
the incidence rate of MD in children
under 1 year ranged between 40 and
69 per 100,000, and in the age group
of 1 to 4 years, between 15 and 30 per
100,000, a definitely higher number
than in other age groups44. In children
under 1 year and in the cases of septi-
cemia, mortality rates due to MD are
also very high when compared to the
rest of the population, reaching 28%
and 40%, respectively1,44-46.
Assuming that MenC is responsi-
ble for at least 40% of all MD cases
and deaths in Brazil, the annual
number of cases and incidence of
death ascribed to that agent is ex-
tremely high (over 2,200 cases and 400
deaths each year). Considering the epi-
demiological hazard caused by the
MenC disease, as well as the safety and
efficacy of the conjugated vaccine,
there is no doubt that this new vaccine
should contribute significantly to the
reduction of morbidity and mortality
caused by MD in this country1. It
should be pointed out that conjugate
vaccines against MenC do not offer
protection against MenB; therefore,
these vaccines will not confer full pro-
tection against MD.
The licensed vaccine has a high
cost (approximately R $140.00), which
should hinder its use in public health.
Additionally, the vaccine is recom-
mended as a 3-dose schedule, intra-
muscular, for infants. Many parents
and doctors may feel reluctant to ad-
minister more injections to such very
young persons.1
Lastly, there are some issues asso-
ciated with the duration of immunity
provided by the vaccine and also with
the impact of immunization in the
community. Since this is a new prod-
uct, the duration of the protection pro-
vided by conjugated vaccines is un-
known10,11. All studies conducted so far
have shown that the conjugated
vaccines against MenC should pro-
vide long-term immunity, just like the
Hib vaccines29-43. However, it is only
through the follow-up of vaccinated
populations that a definitive answer
may be provided in this case1,10,11,39-43.
A few studies have demonstrated
that the new conjugated MenC
vaccines are capable of eliminating
the carrier condition similar to what
occurred with vaccination against
Hib8,9,42,50-52. With the reduction of both
oropharyngeal colonization and the
number of MenC carriers, it is quite
likely that conjugated vaccines will
significantly contribute to herd immu-
nity42,49-52; however, there are some in-
dications that different N. meningitidis
strains may, through a gene exchange
that controls production of the
polysaccharide capsule, switch their
serogroup. The switch of serogroup C
to B and of B to C has already been
confirmed both in vitro and in
vivo4,54,55. The United Kingdom’s Epi-
demiologic Surveillance Service has
not observed this kind of problem so
far. However, it is still unknown
whether massive use of these vaccines
in a set population may cause a selec-
tive pressure for such genetic switches.
Strict epidemiologic surveillance
should be maintained in order to se-
cure early identification of this phe-
nomenon1,39-43,49.
Recommendations for MD preven-
tion
It is estimated that in Brazil, MenC
is responsible for about 2,000 cases of
MD every year. Due to the high preva-
lence and mortality rates of MD, we
consider that the conjugated MenC
vaccine should be primarily prescribed
for children under 5 years, who con-
stitute the largest risk group. The vac-
cine, because of its enhanced
immunogenicity, should also be of-
fered to other risk groups, such as
Table 4 - Meningococcal disease cases
rate, by serogroup. State of São Paulo,
1982 - 2001.
Year Serogroup B Serogroup C
1982 70.1 4.6
1983 77.3 5.9
1984 86.1 3.4
1985 83.1 6.1
1986 63.6 11.0
1987 75.2 10.9
1988 78.5 8.6
1989 76.6 16.6
1990 62.3 33.7
1991 45.8 50.0
1992 57.3 39.5
1993 58.1 39.5
1994 59.7 36.8
1995 57.0 41.8
1996 61.0 36.7
1997 61.2 33.3
1998 62.1 34.4
1999 65.6 30.8
2000 59.9 35.9
2001 56.5 38.4
Source: São Paulo, “Centro de Vigilância
Epidemiológica”, “Serviço de Vigilância
Epidemiológica” (up to 1997) and “Sistema
de Informação de Agravos de Notificação”
(1998 to 2001)/”Divisão de Doenças de
Transmissão Respiratórias)”/“Centro de
Vigilância Epidemiológica”. Data collected
up to 01/31/200246.
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immunocompromised patients (chil-
dren, adolescents, and adults with
complement deficiency, HIV infection,
functional and anatomical asplenia, or
undergoing bone marrow transplanta-
tion). MD risk groups should receive
the quadrivalent vaccine in order to
broaden the protection spectrum
against serogroups A, Y, and W-135,
which are not included in the conju-
gated vaccine against MenC. Polysac-
charide vaccines should only be indi-
cated in the case of epidemics, due to
their low efficacy and lack of induc-
tion of immunologic memory.
It should be emphasized that con-
jugated MenC vaccines provide spe-
cific serogroup protection; therefore,
they will not protect against the
serogroups that are not included in the
vaccine. If MD is suspected in the ab-
sence of prior vaccinations, blood and
liquor culture should be performed,
and treatment should be initiated as
soon as possible. Individuals with in-
timate contacts with MD victims
should receive chemoprophylaxis,
when so indicated, because vaccines
will only give protection after at least
2 weeks, and the majority of second-
ary cases occur during the first 2
weeks after contact20.
It is essential to improve epidemio-
logic surveillance and to establish
laboratories capable of promptly iden-
tifying the primary MD pathogens
with serogrouping and identification
of serogroups, subtypes, and immune
types responsible for the epidemics.
Unfortunately, in Brazil, many of the
MD diagnostics are still based on clini-
cal and laboratory data without isola-
tion of N. meningitidis in culture, and
even when the type of bacteria is iden-
tified, the serogroup is not identified
in most cases.
Regarding the possibility of vacci-
nation against MenB, one of the most
common MD pathogens in Brazil, the
problem is even more serious, because
of the need to identify not only the
serogroup, but also the serotypes,
subtypes, and immune types of that
pathogen. Although, since the 1980’s,
the strain ET-5 has been the most
prevalent cause of epidemics, there is
large variability among the strains that
have been identified in different coun-
tries and at different times1,4,7-9,52,53.
Currently, at least 14 serotypes, 12
subtypes, and 12 immunotypes of
MenB are known. In addition, a large
portion of the invasive disease strains
is still not typed. Consequently, the
indications for vaccination against this
pathogen remain questionable, espe-
cially when the serotype causing the
MD is unknown and the 2-dose regi-
men is used to immunize children un-
der 4 years1,16.
The finding that class-1 OMP pro-
teins play an essential role in the in-
duction of bactericidal antibodies has
stimulated research in the field of poly-
valent vaccines, in an attempt to pro-
vide protection against several
subtypes of MenB. Although it has
been evident that hexavalent vaccines
may induce response to more than one
OMP-1 type57, such vaccines need im-
provement to offer a broader clinical
protection spectrum against the
dreaded MD1-9,48.
By the end of 2000, the genetic
sequencing of N. meningitidis was
completed58,59, and it is expected that
in a few years vaccines with a broader
protection spectrum against several
strains of this bacteria will become
available. In the meantime, it is fun-
damental that the population and doc-
tors watch for the primary signs and
symptoms of the disease to allow a
prompt diagnosis and adequate treat-
ment as well as chemoprophylaxis for
the contacts.
It is estimated that the incidence of
sporadic cases of MD in household
contacts is 4 cases per 1,000 people
exposed, that is, 500 to 800 times
higher than that reported in the popu-
lation as a whole. The majority of sec-
ondary cases occur in the first days af-
ter development of the index case; it
is thus recommended that prophylaxis
be administered early to the following
groups, and if possible, within 24
hours after confirmation of the index
case1-3:
1) household contacts;
2) day care units contacts;
3) people exposed to oral secretions
of infected individuals (kissing,
mouth-to-mouth breathing, en-
dotracheal intubation).
Chemoprophylaxis may be per-
formed with rifampicin, ciprofloxacin,
or ceftriaxone and is 90% to 95% ef-
fective in reducing the N. meningitidis
carrier status. It is recommended up to
14 days after exposure; after this pe-
riod, it is likely that this procedure
will bring little or no benefit to the
contacts. Throat and nasopharyngeal
cultures are of no value for deciding
who should receive chemoprophylaxis
because of the asymptomatic coloni-
zation of the respiratory tract3,4.
Current indications for polysaccha-
ride vaccines:
1. Epidemics: according to the expe-
rience acquired in control of menin-
gococcal C epidemics, an epidemic
is defined as the occurrence of 3 or
more cases (confirmed or probable)
of meningitis caused by this patho-
gen in a period shorter than 3
months or an incidence rate of at
least 10 in 100,000 inhabitants.
This rate is calculated based on the
whole population data and not on
specific age groups. These param-
eters also apply to other meningo-
coccal groups (A, Y, and W135);
2. High-risk groups for meningo-
coccal infections: individuals with
anatomic or functional asplenia de-
ficiency of the terminal section of
complement, as well as individuals
working in laboratories and who
have a greater possibility of expo-
sure to these bacteria;
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3. Military: the high incidence of
MD in non-vaccinated recruits and
the excellent efficacy of MenA and
MenC vaccines warrant indication
for this group;
4. Individuals traveling to hyperen-
demic disease areas or where the
disease occurs as epidemics: espe-
cially those traveling, during the
dry season (December to June) to
Africa’s sub-Sahara, where the dis-
ease is prevalent.
At-risk children, especially if vacci-
nated before they are 4 years, should
be vaccinated again after 2 to 3
years; although there are no studies
on the need to revaccinate individu-
als over 4 years; if they remain as
high-risk individuals, revaccination
may be considered 3 to 5 years after
the initial dose1-3.
RESUMO
BRICKS LF - Análise crítica das anti-
gas e novas vacinas contra a N.
meningitidis do sorogrupo C,
considerando a epidemiologia da
doença meningocócica no Brasil.
Rev. Hosp. Clín. Fac. Med. S.
Paulo 58 (4):231-240, 2003.
Em todo o mundo, o impacto das
doenças meningocócicas é enorme e o
potencial para a introdução e dissemi-
nação de cepas da N. meningitidis mais
virulentas ou com aumento da resistên-
cia aos antibióticos atualmente utili-
zados causa grande preocupação, tor-
nando a prevenção essencial.
OBJETIVO: Rever as indicações
das vacinas para doenças meningo-
cócicas, considerando a situação epi-
demiológica do Brasil.
MÉTODOS: Revisão crítica sobre
o tema, usando as bases de dados
Medline e Lilacs.
RESULTADOS: Os sorogrupos B
e C foram os mais prevalentes no Bra-
sil, na década de 90. As vacinas polis-
sacarídicas disponíveis contra esses
sorogrupos oferecem proteção limita-
da aos lactentes e podem induzir tole-
rância ao MenC. As novas vacinas
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conjugadas contra o MenC podem so-
lucionar parcialmente esse problema,
mas é improvável que, em curto pra-
zo, sejam licenciadas novas vacinas
contra o MenB.
CONCLUSÕES: Para tomar as me-
lhores decisões sobre as recomenda-
ções em práticas de imunização, é ne-
cessário que se disponha de dados pre-
cisos da vigilância epidemiológica,
com identificação dos sorogrupos mais
prevalentes em cada faixa etária. Esti-
ma-se que, no Brasil, o MenC seja res-
ponsável por 2.000 casos de doenças
meningocócicas , a cada ano. As no-
vas vacinas conjugadas contra o
MenC são seguras, efetivas e imuno-
gênicas, devendo ser recomendadas,
particularmente, para crianças menores
de 5 anos. As vacinas polissacarídicas
devem ser recomendadas apenas para
os grupos de alto risco ou em situa-
ções epidêmicas. Enquanto novas va-
cinas contra o MenC e MenB não fo-
rem incorporadas ao calendário de va-
cinação de rotina, as mais efetivas me-
didas para controlar as doenças menin-
gocócicas são o diagnóstico e trata-
mento precoces e a quimoprofilaxia
para contactantes.
DESCRITORES: N. meningitidis.
Epidemiologia. Vacina. Eficácia.
Crianças.
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